Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNMT siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral
01
Overview
NNMT siRNA refers to a class of small interfering RNA (siRNA) molecules designed to silence the expression of the Nicotinamide N-Methyltransferase (NNMT) gene via RNA interference (RNAi). NNMT is a metabolic enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosyl-L-homocysteine (SAH). Upregulation of NNMT has been implicated in metabolic disorders such as obesity and insulin resistance, as well as various cancers including glioblastoma, colorectal cancer, and renal cell carcinoma, where it promotes tumor cell proliferation, invasion, and therapeutic resistance. NNMT siRNA is widely utilized as a research tool to study the biological consequences of NNMT knockdown in vitro and in preclinical animal models. As of 2024, no NNMT-targeting siRNA has advanced to clinical trials, and these reagents are primarily available through research-use-only suppliers like Santa Cruz Biotechnology and MedChemExpress.
- Other names
- Nicotinamide N-methyltransferase siRNAsiRNA-NNMT
02
Targets
NNMT (Nicotinamide N-methyltransferase)
Beyond the preview
Go deeper on NNMT siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNMT siRNA.